A systematic review demonstrates that susceptibility-guided therapy achieves superior eradication in adults, suggesting its integration in treatment plans.
In adult first-line therapy, SGT achieves at least non-inferior-and often superior-eradication versus empirical regimens; the incremental benefit is attenuated where BQT is standard. These findings support selective, and increasingly justified, integration of susceptibility testing in settings with clinically relevant resistance.
No takes yet. Share an insight, caveat, or question.
Rocha et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: